| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Belantamab Mafodotin
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Shaanxi Dideu Medichem Co. Ltd
|
| Tel: |
029-029-81124267 15229202216 |
| Email: |
1073@dideu.com |
| Products Intro: |
Product Name:belantamab mafodotin
CAS:2050232-20-5
Purity:99% Package:25KG/桶
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Belantamab mafodotin
CAS:2050232-20-5
Purity:95% Package:1mg/RMB 2980;5mg/RMB 6690
|
| Company Name: |
Wuhan Peptide Core Biotechnology Co., Ltd
|
| Tel: |
027-65317797 13667154760 |
| Email: |
1096814016@qq.com |
| Products Intro: |
Product Name:Belantamab mafodotin (ADC)
Purity:>95%asdeterminedbySDS-PAGE. Package:100ug;1mg
|
Belantamab Mafodotin manufacturers
- Belantamab Mafodotin
-
- $0.00 / 25kg
-
2025-05-12
- CAS:2050232-20-5
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000KGS
Related articles - Synthesis of Belantamab Mafodotin
- Belantamab Mafodotin is prepared by combining mafodotin with the monoclonal antibody belantamab. A drug linker technology was ....
- Dec 28，2023
|
| | Belantamab Mafodotin Basic information |
| | Belantamab Mafodotin Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Belantamab Mafodotin Usage And Synthesis |
| Uses | Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. Belantamab mafodotin has anti-myeloma activity[1][2]. | | in vivo | Belantamab mafodotin signifcantly improves survival compared to vehicle in mice harbouring OPM2 tumours[2]. | Animal Model: | Mice harbouring OPM2 tumours[2] | | Dosage: | 4 mg/kg | | Administration: | IP, twice weekly for 4 doses | | Result: | Signifcantly improves survival compared to vehicle. |
| | References | [1] Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. DOI:10.1016/S1470-2045(19)30788-0
[2] Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. DOI:10.1007/s40265-020-01404-x |
| | Belantamab Mafodotin Preparation Products And Raw materials |
|